Inflazome
Targeting inflammation at its source.
- Headquarters
- Dublin
- Employees
- 11–50
- Founded
- 2016
- Business Model
- B2B
- Website
- inflazome.com
- Total Funding
- $63.0M
- Last Round
- $63.0M Series BNov 2018
About
Inflazome was a Dublin-based biotech company developing orally available small molecule NLRP3 inflammasome inhibitors to treat chronic inflammatory diseases including Parkinson's, Alzheimer's, arthritis, and cardiovascular conditions. Founded in 2016 by Prof. Matt Cooper and Prof. Luke O'Neill, the company advanced two clinical-stage drugs before being acquired by Roche for €380 million in 2020.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Sign up to view funding details
Create a free account to see full funding history, valuations, and investor participation.
Create Free Account